Events

Join us for a KOL Event with Protalix Biotherapeutics, featuring Myrl D. Holida, PA (University of Iowa Stead Family Children’s Hospital) who will discuss the PRX-102 robust clinical program for the potential treatment of patients suffering from Fabry disease. Members of the Protalix Biotherapeutics leadership team will provide a regulatory update regarding PRX-102, its investigational…

Join us for a virtual KOL Event with Vaccitech, featuring Robert Anderson, MD, PhD (Novoviah Pharmaceuticals, Brisbane, Australia) and Professor Christopher Jewell, PhD (University of Maryland) who will discuss the unmet needs and current status of treatments for celiac disease and other autoimmunity indications, along with the potential for tolerogenic immunotherapies in the current treatment landscape.…

Please join Xilio Therapeutics for a virtual program spotlight on XTX301:A Tumor-Activated IL-12 featuring Key Opinion Leader (KOL) Diwakar Davar, MBBS, M.Sc (UPMC Hillman Cancer Center), who will discuss the current landscape and unmet medical need present in treating patients with advanced solid tumors and Xilio’s potential therapeutic solution, XTX301 The Xilio leadership team will highlight the…

LifeSci Partners is pleased to announce the return of our in-person Corporate Access Event in San Francisco during the week of The JP Morgan Healthcare Conference. The event will feature more than 200 innovative publicly traded & privately held biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe. The event…

Join us for a virtual KOL event featuring Jonathan Barratt, PhD, FRCP (University of Leicester) who will discuss the disease burden and pathogenesis of IgA nephropathy (IgAN), as well as atacicept’s clinical data to-date. Atacicept is a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a…

Join us for the Sensei Biotherapeutics KOL Event, featuring Robert Schreiber, PhD (Washington University School of Medicine) who will provide background on VISTA (V-domain Immunoglobulin Suppressor of T cell Activation) and discuss the unmet medical needs present in the current immuno-oncology treatment landscape, and the importance of VISTA in developing highly selective therapeutics in cancer. The Sensei Biotherapeutics leadership team will provide…

8:30 AM ET – Breakfast/Check-In 9:00 AM ET – 11:00 AM ET – Presentations Y-mAbs Therapeutics invites you to their annual R&D Day, featuring presentations of the company, its clinical development and advanced product pipeline. Company Presenters: Thomas Gad (Founder, President, and Interim Chief Executive Officer at Y-mAbs Therapeutics) will give a corporate presentation. Steen Lisby,…

Further information regarding the event to be provided at a later date. CONTACT US Investor Inquiries: investor@ideayabio.com The post IDEAYA Biosciences Investor R&D Day appeared first on LifeSci Events. The post IDEAYA Biosciences Investor R&D Day appeared first on LifeSci Advisors.